Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2007 September 4; 117(9): 2553–2561.
Published online 2007 September 4. doi:  10.1172/JCI32959
PMCID: PMC1957545

Recovery from diabetes in mice by β cell regeneration


The mechanisms that regulate pancreatic β cell mass are poorly understood. While autoimmune and pharmacological destruction of insulin-producing β cells is often irreversible, adult β cell mass does fluctuate in response to physiological cues including pregnancy and insulin resistance. This plasticity points to the possibility of harnessing the regenerative capacity of the β cell to treat diabetes. We developed a transgenic mouse model to study the dynamics of β cell regeneration from a diabetic state. Following doxycycline administration, transgenic mice expressed diphtheria toxin in β cells, resulting in apoptosis of 70%–80% of β cells, destruction of islet architecture, and diabetes. Withdrawal of doxycycline resulted in a spontaneous normalization of blood glucose levels and islet architecture and a significant regeneration of β cell mass with no apparent toxicity of transient hyperglycemia. Lineage tracing analysis indicated that enhanced proliferation of surviving β cells played the major role in regeneration. Surprisingly, treatment with Sirolimus and Tacrolimus, immunosuppressants used in the Edmonton protocol for human islet transplantation, inhibited β cell regeneration and prevented the normalization of glucose homeostasis. These results suggest that regenerative therapy for type 1 diabetes may be achieved if autoimmunity is halted using regeneration-compatible drugs.


Our understanding of the determinants of tissue mass during adult life is still rudimentary. Insights into this problem may suggest novel approaches for the treatment of neoplastic as well as degenerative diseases. In the case of the pancreas, elucidating the mechanisms that govern β cell mass will be important for the design of regenerative therapy for both type 1 and type 2 diabetes, diseases characterized by an insufficient mass of β cells (1). It is clear that β cell mass increases during pregnancy (24) and in insulin-resistant states (58), but evidence on the ability of β cells to regenerate from a severe, diabetogenic injury is conflicting.

Whereas autoimmune diabetes is normally irreversible, recent evidence from both humans (912) and rodents (1318) suggests that β cell function (i.e., insulin production and the maintenance of glucose homeostasis) can partly recover if autoimmunity is blocked. However, most studies have not directly assessed the regeneration of β cell mass (as opposed to recovery of dysfunctional cells). Another outstanding issue is the cellular origins of β cells in adults (19, 20). We previously employed genetic lineage tracing in mice to demonstrate that proliferation of differentiated β cells, rather than differentiation of stem cells, is the major mechanism for maintenance of adult β cell mass (21). That study did not eliminate the possibility that under certain conditions, yet to be identified, facultative stem cells might exist and give rise to new β cells (19, 20). In any case, the mechanisms that sense β cell mass and operate to achieve homeostasis are largely unknown (22). Here we describe a transgenic mouse system for the specific and conditional ablation of β cells that allows us to address some of these issues without the complications of an ongoing autoimmune attack. We found that mice spontaneously recovered from diabetes by β cell regeneration, mediated by the enhanced proliferation of surviving β cells. The standard immune suppression drugs Sirolimus and Tacrolimus abolished β cell regeneration, indicating that regeneration-compatible immune suppression drugs will be required for successful regenerative therapy for type 1 diabetes.


Conditional ablation of pancreatic β cells.

We reasoned that a useful model to study β cell regeneration would permit: (a) specific killing of β cells; (b) temporal control over the onset of cell killing; (c) absolute ability to terminate injury; and (d) a binary mode of β cell injury (e.g., β cells will be either killed or unharmed). Using such a system, one should be able to eliminate a significant fraction of β cells at a desired time and then characterize regeneration in the absence of the confounding effects of autoimmunity, accompanying damage to other cell types, or recovery of dysfunctional β cells. Our strategy was based on doxycycline-induced expression of diphtheria toxin in β cells. We combined a transgenic mouse strain that expresses the reverse tetracycline-dependent transactivator in β cells (Insulin-rtTA; in which rtTA expression is driven by 9.5 kb of the 5′ flanking region of the rat insulin II gene) (23, 24) with a strain that expresses the diphtheria toxin A (DTA) subunit under a rtTA-responsive promoter (TET-DTA) (25) (Figure (Figure1A).1A). In the presence of doxycycline, rtTA induces the expression of DTA, causing β cell apoptosis. Because a single molecule of DTA suffices to kill a cell (26), sublethal β cell damage was not expected. Control experiments showed that in the absence of doxycycline, double-transgenic Insulin-rtTA;TET-DTA mice were indistinguishable from wild-type mice in terms of glucose homeostasis as well as islet histology (Figure (Figure1,1, B–D). As early as 48 hours after the administration of doxycycline to adult double-transgenic mice, widespread apoptosis restricted to β cells was observed. No apoptosis was seen in islets of cotreated single-transgenic littermates (Figure (Figure1,1, E and F, and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI32959DS1). These results confirm that the ablation system was tightly controlled by doxycycline and was β cell specific.

Figure 1
A transgenic mouse system for specific and conditional ablation of pancreatic β cells.

We assessed the histological and physiological consequences of β cell killing. Four-week-old mice were treated with doxycycline for 1 week and sacrificed at 5 weeks of age. Islet architecture in such transgenic mice was severely disrupted, with non-β cells located at the core of shriveled islets, whereas the islet core was normally occupied by β cells (Figure (Figure2,2, A and B). Morphometric quantification of β cell mass revealed the loss of 70%–80% of β cells compared with control littermates (Figure (Figure2,2, D and F). Pancreatic insulin content was reduced by about 85% (Figure (Figure2G),2G), and blood glucose levels were elevated to 300–600 mg/dl, rendering the mice overtly diabetic (Figure (Figure2H).2H). A slight, statistically insignificant, increase in α cell mass was noted (Supplemental Figure 4E).

Figure 2
Ablation and regeneration of β cells.

Spontaneous regeneration of β cells.

Surprisingly, following withdrawal of doxycycline the mice regained normal blood glucose levels. A spontaneous normalization of islet architecture occurred in more than 90% of islets (Figure (Figure2,2, A–C, and Supplemental Figure 4C), and β cell mass increased to levels comparable to those of wild-type littermates (Figure (Figure2,2, D–F), as did pancreatic insulin levels (Figure (Figure2G).2G). The distribution of islet sizes also returned to normal (Supplemental Figure 2I). These changes accompanied a spontaneous remission of hyperglycemia, such that fed and fasting blood glucose levels normalized (Figure (Figure2H).2H). With very long recovery periods (more than 8 months), glucose tolerance of transgenic mice began to recover (Figure (Figure2I).2I). Similar results were obtained when β cells were ablated between birth and 5 weeks of age; in this case, β cell mass normalized within about 15 weeks of doxycycline withdrawal (Supplemental Figure 2). Even mice that had severe (greater than 450 mg/dl), chronic (lasting more than 4 months), or adult-onset (starting at 4 months of age) hyperglycemia spontaneously normalized their blood glucose levels and β cell mass after doxycycline withdrawal (Supplemental Figure 3 and data not shown). The average size of individual β cells did not change after regeneration, nor did peripheral insulin sensitivity (Supplemental Figure 4, B and D). These results provide direct evidence that there is a significant capacity for the regeneration of pancreatic β cells following a diabetogenic injury.

Origin of new β cells.

We sought to identify the cellular source responsible for β cell regeneration in this model. The rate of β cell apoptosis was not reduced in recovering mice compared with controls (measured by TUNEL staining; data not shown), suggesting that regeneration results from accelerated formation, rather than extended life span, of β cells.

Staining for Ki67 and insulin revealed that the β cell proliferation rate increased 2- to 3-fold as early as 48 hours after the onset of β cell ablation, even before hyperglycemia was detected (Figure (Figure3,3, A and B). Proliferation of β cells persisted at this higher level for several weeks. Similar results were obtained with BrdU staining in mice injected with BrdU 3 hours prior to sacrifice (data not shown). Interestingly, cells in the exocrine pancreas, but not in the main ducts, had a transient increase in proliferation rate during the peak of β cell ablation (Figure (Figure3C3C and data not shown). Consistent with the transient nature of this wave of proliferation, overall pancreas weight did not change during ablation and regeneration. The global and transient proliferative response in the pancreas may be related to inflammation that develops as large numbers of dead β cells are removed. In agreement with this idea, β cell ablation led to the accumulation of F4/80+ macrophages in the pancreas as early as 48 hours after the addition of doxycycline (Supplemental Figure 5).

Figure 3
Cell proliferation during regeneration.

We assayed for putative pancreatic progenitor cells during β cell regeneration. Immunostaining and RT-PCR revealed no upregulation of the embryonic endocrine progenitor cell marker neurogenin 3 (Ngn3) in regenerating pancreata, although Ngn3 expression was readily detected in the embryonic pancreas (Supplemental Figure 6). In addition, the expression pattern of the transcription factor Pdx1, known to be expressed in progenitor cells of the embryonic pancreas, did not differ between wild-type and transgenic mice (Supplemental Figure 6). We also searched for cells that coexpress insulin and other endocrine hormones, proposed by some to represent endocrine progenitor cells (27). The frequency of insulin+/glucagon+ cells increased from 1:5,500 β cells in wild-type mice to 1:1,000 β cells in diabetic mice (Supplemental Figure 6). If these double-hormone-positive cells are progenitor or precursor cells, as opposed to dead-end pathways (27), their numbers in this context appear too low to make a significant contribution to β cell regeneration. These results indicate that increased self-duplication of surviving β cells is the simplest explanation for β cell regeneration. Nonetheless, the relative importance of β cell proliferation versus differentiation or transdifferentiation of other cell types is difficult to discern from histological analysis and gene expression patterns. We therefore used genetic lineage tracing as a rigorous test for the cellular origins of new β cells in this model.

As described previously (21), we used Insulin-CreERTM transgenic mice, in which the insulin promoter drives the expression of tamoxifen-dependent Cre recombinase (CreERTM) in β cells. To allow for pulse labeling of differentiated β cells, we combined this strain with the Z/AP Cre reporter strain (21) to generate Insulin-CreERTM;Z/AP mice. The injection of tamoxifen into such mice leads to the transient activation of Cre recombinase exclusively in insulin-expressing cells. This results in removal of a transcriptional stop sequence from the Z/AP transgene and constitutive expression of the human placental alkaline phosphatase (HPAP) reporter gene in β cells and their progeny (Figure (Figure4A).4A). Thus, HPAP expression in β cells born at any time after tamoxifen injection identifies these cells as the progeny of preexisting Cre-expressing cells. We bred compound transgenic mice containing both the ablation system (Insulin-rtTA;TET-DTA) and the lineage tracing system (Insulin-CreERTM;Z/AP). To identify the source of new β cells during regeneration, β cells were ablated by treating newborn mice with doxycycline for 45 days, which rendered them diabetic. During the last 10 days of doxycycline treatment (age 35–45 days), surviving β cells were labeled by a series of 5 tamoxifen injections, after which doxycycline was withdrawn to allow for regeneration. During the course of regeneration, mice received BrdU in the drinking water to label new β cells, born by replication from any cellular source (Figure (Figure4A).4A). After 2 weeks mice were sacrificed, and the proportion of HPAP+ β cells among all β cells and among the new (i.e., BrdU+) β cells was determined. As shown in Figure Figure4B,4B, a lower proportion of HPAP+ cells among new β cells would indicate that non-β cells are contributing to β cell regeneration. Figure Figure4C4C shows a representative confocal image of an islet stained for insulin, HPAP, and BrdU. Note that only about 20% of β cells were labeled by HPAP (as a result of Cre activity), because of the inefficiency of the tamoxifen-induced Cre-mediated recombination. It should be emphasized that this recombination rate is sufficient to be informative, because for this analysis the ratio of HPAP+ cells in all β cells to that in new β cells is the key parameter.

Figure 4
New β cells come predominantly from preexisting β cells.

The results of the experiment are summarized in Figure Figure4D.4D. In 5 independent Insulin-rtTA;TET-DTA;Insulin-CreERTM;Z/AP compound transgenic mice, the proportion of HPAP+ cells among new β cells was similar to the overall efficiency of recombination in that mouse. Stated another way, if the recombination efficiency were 100%, nearly all new β cells would be HPAP+, the progeny of surviving β cells that proliferated. The proportion of new β cells among the HPAP+ population was similar to the proportion of new β cells among the general β cell population (BrdU incorporation in 21%–24% of both recombined HPAP+ and unrecombined β cells). As shown in Figure Figure4B,4B, this result indicates that new β cells in regenerating islets are largely, and perhaps exclusively, derived from β cells that survived ablation. There is no evidence for new β cell differentiation from a stem cell, as this would be associated with a lower proportion of HPAP expression in the BrdU+ β cell population. When the experimental protocol was modified such that β cells were heritably labeled prior to the onset of β cell ablation, similar results were obtained (data not shown). We conclude that β cell proliferation is the major source of new β cells and can account for the regeneration observed in this model.

Immune suppressants abolish β cell regeneration.

This β cell ablation system provides a screening platform for factors and drugs that affect β cell regeneration. The Edmonton protocol for islet transplantation greatly improved the success of human islet transplants, as a result of better islet preparation techniques and the use of the nonsteroidal immune suppressants Sirolimus (also known as rapamycin) and Tacrolimus (also known as FK-506) (28). However, most patients lose graft function over time, a phenomenon usually ascribed to either allo- or autoimmunity (2931). We used our conditional ablation-regeneration system to ask whether these drugs might additionally interfere with β cell regeneration. Transgenic mice were rendered diabetic by the administration of doxycycline from birth to 1 month and were then allowed to recover in the absence or presence of clinically relevant doses of Sirolimus and Tacrolimus (SirTac; see Methods) (32, 33). Mice were sacrificed either 2 weeks after doxycycline withdrawal to observe β cell proliferation, or 2 months after doxycycline withdrawal to observe changes in blood glucose and β cell mass. In the former experiment, BrdU was added to the drinking water for 2 weeks to document the accumulation of new β cells. As shown in Figure Figure5,5, A–C, SirTac drastically reduced the β cell proliferation rate (the fraction of Ki67+ β cells) as well as β cell accumulation (the fraction of BrdU+ β cells) in diabetic mice and to a lesser extent in wild-type mice. The rate of β cell apoptosis did not increase following SirTac administration (data not shown), suggesting that at the doses used, the effect of these drugs on β cell number is primarily via reduced proliferation. Figure Figure5D5D shows that while wild-type islets appeared grossly normal after 2 months’ treatment with SirTac, islet architecture in diabetic mice treated with SirTac failed to normalize. Accordingly, β cell mass in SirTac-treated mice did not increase upon doxycycline withdrawal (Figure (Figure5E).5E). As a result, diabetic mice treated with SirTac failed to normalize blood glucose during a period in which untreated diabetic littermates recovered spontaneously (Figure (Figure5F).5F). Notably, at the dose and time used, wild-type mice receiving SirTac remained normoglycemic. The results indicate that this commonly used immune suppression protocol prevents β cell regeneration. This may provide a partial alternative explanation for islet graft failure in the Edmonton protocol and for posttransplantation diabetes.

Figure 5
SirTac inhibits β cell regeneration.


Spontaneous regeneration of pancreatic β cells.

The results presented here show that pancreatic β cells have a significant capacity for spontaneous regeneration, sufficient for recovery from overt diabetes. This contrasts with the failure of β cell regeneration in both autoimmune and pharmacological models of diabetes, which has led to the common perception that β cells have a poor or non-existent regenerative capacity. We suggest that in existing mouse models for, and human patients with, type 1 diabetes confounding factors mask the innate regenerative response of β cells. In autoimmune diabetes, persistent autoreactive T cells may continually eliminate regenerating β cells. Consistent with this proposition, recently reported results from an autopsy provided evidence for ongoing, albeit futile, attempts for β cell regeneration in a type 1 diabetes patient (34), as well as for β cell formation even in long-time diabetics, formerly believed to be devoid of β cells (35). In addition, protocols for blocking autoimmunity in humans with type 1 diabetes (911) and in NOD mice (1318, 36) result in some degree of remission from diabetes, although most of these studies did not distinguish between an increase in β cell mass (true regeneration) and physiological recovery of dysfunctional β cells (36). Finally, diabetes induced by injection of β cell toxins, including streptozotocin and alloxan, is also largely irreversible. In these cases, we suggest that all β cells, including any that survive the toxic insult, may have suffered irreversible damage that prevents subsequent divisions needed for regeneration (37). This proposition is consistent with the conclusion that surviving β cells represent the major cellular pool responsible for regeneration. Our DTA-mediated β cell ablation system may allow for β cell regeneration as a result of the tight control over the duration of insult and the fact that surviving β cells do not suffer sublethal damage (26).

Cellular origins of new β cells.

The identity of the cellular origins for new β cells has been controversial (19, 20). We previously used genetic lineage tracing to show that proliferation of differentiated β cells is the major mechanism for β cell formation during adult life in the mouse (21). More recent studies further concluded that all β cells have an equal potential for proliferation (3841). However, it remains possible that rare facultative stem cells, yet to be identified, are activated in the pancreas following specific injury conditions (19, 20). The ablation system described here provides a particularly useful setting, in which the magnitude of β cell regeneration sufficed to cure diabetes. Several lines of evidence support the conclusion that in this model, proliferation of differentiated β cells is the predominant mechanism of regeneration. First, we observed that β cell ablation led to a rapid increase in β cell proliferation rate, preceding any change in the proliferation of non-β cells. Second, markers of embryonic-type pancreatic progenitor cells (Ngn3 and Pdx1) were not activated during the course of β cell ablation and regeneration. Third, genetic lineage tracing showed that most new β cells formed during regeneration were the progeny of differentiated β cells that survived ablation. Nevertheless, we cannot exclude the possibility of a small contribution of non-β cells to β cell regeneration in this model. It is also possible that under other settings, perhaps involving near-total ablation of β cells, stem cells or other non-β cell types can contribute to β cell regeneration. In addition, regeneration could involve the transient dedifferentiation of β cells followed by proliferation and redifferentiation (42, 43), although our observation of multiple proliferating insulin+ β cells argues against this interpretation. Notably, recent lineage tracing studies of cultured β cells found little evidence for the proliferation of dedifferentiated β cells (4447).

Determinants of β cell regeneration.

The ablation system described here allows for studying signals that trigger and control β cell regeneration. The results provide some interesting hints regarding this challenging problem. First, the β cell proliferation rate increased rapidly after β cell killing, prior to any observed systemic perturbation of glucose physiology. This suggests that local processes within damaged islets play a role in β cell regeneration. We speculate that the disruption of islet architecture, that is, the apposition of β cells to blood vessels or to other endocrine cells, can trigger a regenerative response. Alternatively, dying β cells could provide a mitogenic signal to adjacent β cells, analogous to the induction of mitosis in the embryonic Drosophila wing by apoptotic cells (48). Such a mechanism could be acting normally to maintain the correct number of β cells independent of fluctuations in blood glucose levels. Second, the spontaneous recovery from severe hyperglycemia (often greater than 500 mg/dl for several weeks) challenges the widely held view that glucotoxicity is a major barrier for β cell proliferation in vivo and a cause for β cell failure in type 2 diabetes (49). Third, the observed recovery of adult mice (up to 4 months of age) from diabetes argues against an age-associated decline in the regenerative capacity of β cells (50). More experiments are needed to determine whether older mice retain the ability to regenerate their β cells. Fourth, the slow kinetics of β cell regeneration (several months) distinguish this mode of regeneration from other settings of mammalian solid tissue regeneration such as posthepatectomy liver regeneration (51) or postcaerulein regeneration of the exocrine pancreas (52), both of which occur in a few days. This might be related to the metabolic burden on surviving β cells or to antiproliferative mechanisms permitting the cell-cycle entry of a small proportion of β cells at a given time (40). Reducing hyperglycemia in DTA mice by the transplantation of exogenous islets could provide insights into the impact of metabolic stress and glucose physiology on β cell regeneration. Finally, the prevention of regeneration by SirTac suggests a key role for the targets of these drugs, namely mammalian target of rapamycin and calcineurin pathways, in β cell proliferation and regeneration. This is consistent with results of studies in rodents and humans that documented a negative effect of the Edmonton protocol on glucose physiology and β cell function (33, 53) and showed a role for calcineurin in β cell proliferation (54). Nonetheless, to our knowledge, the effect of these drugs on β cell regeneration after injury was not addressed before. More experiments are needed to determine the toxicity of rapamycin and FK-506 given individually and to establish whether they affect regeneration by acting directly on β cells or via a non–cell autonomous mechanism (e.g., inhibition of islet angiogenesis).

Clinical implications.

Our results have a number of implications for regenerative therapy in diabetes. Most importantly, the demonstrated regenerative capacity of β cells provides an encouraging proof of concept for regenerative medicine approaches to diabetes treatment. The finding that recovery from a diabetogenic injury occurred spontaneously in both adult and neonatal mice and that it was not prevented by glucotoxicity further indicates that β cell regeneration is a robust biological response that can potentially be used therapeutically. The reliance of regeneration on proliferation of surviving β cells underscores the importance of diagnosis and intervention early in the course of autoimmune diabetes, before β cells are totally eliminated. These experiments also uncover an unanticipated toxic effect of the common nonsteroidal immunosuppressants Sirolimus and Tacrolimus on β cell regeneration. This begs the question of whether one can find other immunosuppressants that are compatible with β cell regeneration. Furthermore, the results raise the interesting possibility that, in addition to allo- and autorejection, current long-term islet transplantation failure has an iatrogenic component of compromised β cell turnover in the graft. Altering the immune suppression component of the Edmonton protocol may significantly prolong graft survival and function.



Animal care and experiments were approved by the Institutional Animal Care and Use Committee of the Hebrew University. Transgenic mice were genotyped by PCR on ear punches using the following primers: TET-DTA (25), 5′-TTTTGACCTCCATAGAAGAC-3′ and 5′-GGCATTATCCACTTTTAGTGC-3′; Insulin-rtTA (23), 5′-TAGATGTGCTTTACTAAGTCATCGCG-3′ and 5′-GAGATCGAGCAGGCCCTCGATGGTAG-3′; Insulin-CreERTM (21), 5′-TGCCACGACCAAGTGACAGC-3′ and 5′-CCAGGTTACGGATATAGTTCATG-3′. Z/AP mice (55) were identified by performing X-gal staining on tail biopsies. Doxycycline (Dexon) was administered in the drinking water (200 μg/ml doxycycline, 2% w/v sucrose). Water was changed every 5 days. In our routine protocol, 4-week-old mice were treated with doxycycline for 7 days and then sacrificed or allowed to recover, in the absence of doxycycline, for 5–7 months. In some experiments, mice received doxycycline (via the drinking water of the mother) between birth and 4 weeks of age (Figure (Figure5),5), between birth and 5 weeks of age (Supplemental Figure 2), or between birth and 45 days of age (Figure (Figure4).4). Tamoxifen (Sigma-Aldrich) was dissolved in corn oil to 20 mg/ml and injected subcutaneously over 10 days in 5 doses of 8 mg each. Glucose tolerance tests were performed by injecting glucose (2 mg/kg) intraperitoneally after overnight fasting. Insulin sensitivity was determined by injecting insulin (Humalog, 0.75 U/kg; Eli Lilly). For the SirTac experiments we followed an earlier study that adapted the human protocol to mice (32). Briefly, Rapamune (LC Laboratories) was loaded at 0.3 mg/kg on day 1, followed by 0.15 mg/kg every other day until day 26, then reduced to 0.1 mg/kg for subsequent loading. Tacrolimus (Prograf; Astellas) was injected daily at 1 mg/kg. BrdU (Sigma-Aldrich) was either injected intraperitoneally (100 mg/kg) 3 hours prior to sacrifice or administered in the drinking water (0.8 mg/ml). Water was changed every 5 days.


Paraffin sections (5 μm thick) were rehydrated, and antigen retrieval was performed using a PickCell pressure cooker. The following primary antibodies were used: guinea pig anti-insulin (1:200; DAKO), rabbit anti-glucagon (1:200; DAKO), rabbit anti-somatostatin (1:200; Zymed), rabbit anti–pancreatic polypeptide (1:200; Zymed), mouse anti-BrdU (cell proliferation kit, 1:300; Amersham), rabbit anti-ki67 (1:200; Neo markers), mouse anti–E-cadherin (1:50; BD), rabbit anti-HPAP (1:100; Zymed), guinea pig anti-Pdx1 (1:2,500; a generous gift of Chris Wright), mouse anti-Ngn3 (1:2,000; a generous gift of Ole Madsen, Beta Cell Biology Consortium), and rat anti-F4/80 (1:50; Serotec). For DNA counterstain we used either propidium iodide (2 μg/ml) or Toto3 (1:500; Molecular Probes). TUNEL staining was performed using the Roche cell death detection kit. Secondary antibodies were all from Jackson Immunoresearch Laboratories. For double staining we used only affinity-purified secondary antibodies, suitable for multiple labeling. As an alternative method to detect HPAP+ cells we applied the alkaline phosphatase chromogenic substrate BCIP/NBT as previously described (21). All immunofluorescence images were captured on a Nikon C1 confocal microscope. To determine β cell mass, consecutive paraffin sections 75 μm apart spanning the entire pancreas (approximately 9 sections/pancreas) were stained for insulin and hematoxylin. Digital images of sections at a magnification of ×40 were obtained and stitched using NIS-Elements software, and the fraction of tissue covered by insulin staining was determined. The mass of β cells was calculated as the product of pancreas weight and the fraction of tissue covered by β cells. Control experiments showed that interindividual variation in β cell mass (normalized to body weight) was about 10% in C57BL/6 mice and 25% in ICR mice (Supplemental Figure 4F). Insulin levels in the pancreas and in the serum were determined using an ultrasensitive insulin ELISA kit (Chrystal Chem). The degree of islet organization was quantified by applying a MATLAB algorithm to digital fluorescent images of islets stained for insulin and glucagon. Briefly, the algorithm determines the probability that the spatial distribution of glucagon+ cells within the islet is random. The more restricted α cells are to the periphery of an islet, the lower the probability that this islet is a random mix of endocrine cells. RNA was prepared from whole adult pancreata using the Qiagen RNEasy kit. Taqman analysis was used to determine the levels of Ngn3 normalized to mTBP.


Statistical analyses were performed using 2-tailed Student’s t test. A P value less than 0.05 was considered significant. Data are presented as mean ± SD.

Supplementary Material

Supplemental data:


We thank Massimo Trucco and Decio Eizirik for stimulating discussions and Glenn Fishman, Ron DePinho, Gerhard Christofori, Andras Nagy, Chris Wright, and Ole Madsen for sharing mice and antibodies. We are grateful to Tommy Kaplan, Olga Martinez, Shay Porat, Alon Rasuli, Miri Stolovich-Rain, Avital Swisa, and Bat-Sheva Werman for assistance in various experimental procedures and to Jay Rajagopal, Howard Cedar, Ittai Ben-Porath, and Ben Stanger for critical reading of the manuscript. This work was supported by the Beta Cell Biology Consortium (Y. Dor and D.A. Melton) and by grants from the Juvenile Diabetes Research Foundation, Israel Science Foundation, D-Cure, and the EU BetaCellTherapy consortium (Y. Dor). D.A. Melton is a Howard Hughes Medical Institute Investigator.


Nonstandard abbreviations used: DTA, diphtheria toxin A; HPAP, human placental alkaline phosphatase; SirTac, Sirolimus and Tacrolimus.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:2553–2561 (2007). doi:10.1172/JCI32959


1. Rood P.P., et al. Facilitating physiologic self-regeneration: a step beyond islet cell replacement. Pharm. Res. 2006;23:227–242. [PubMed]
2. Parsons J.A., Brelje T.C., Sorenson R.L. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology. 1992;130:1459–1466. [PubMed]
3. Parsons J.A., Bartke A., Sorenson R.L. Number and size of islets of Langerhans in pregnant, human growth hormone-expressing transgenic, and pituitary dwarf mice: effect of lactogenic hormones. Endocrinology. 1995;136:2013–2021. [PubMed]
4. Gupta R.K., et al. Expansion of adult beta-cell mass in response to increased metabolic demand is dependent on HNF-4alpha. Genes Dev. 2007;21:756–769. [PubMed]
5. Maclean N., Ogilvie R.F. Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes. 1955;4:367–376. [PubMed]
6. Butler A.E., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110. [PubMed]
7. Kulkarni R.N., et al. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J. Clin. Invest. 2004;114:828–836. doi: 10.1172/JCI200421845. [PMC free article] [PubMed] [Cross Ref]
8. Flier S.N., Kulkarni R.N., Kahn C.R. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc. Natl. Acad. Sci. U. S. A. 2001;98:7475–7480. [PubMed]
9. Herold K.C., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–1769. [PubMed]
10. Herold K.C., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002;346:1692–1698. [PubMed]
11. Bresson D., et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 2006;116:1371–1381. doi: 10.1172/JCI27191. [PMC free article] [PubMed] [Cross Ref]
12. Voltarelli J.C., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568–1576. [PubMed]
13. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 1994;91:123–127. [PubMed]
14. Kodama S., Kuhtreiber W., Fujimura S., Dale E.A., Faustman D.L. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science. 2003;302:1223–1227. [PubMed]
15. Nishio J., et al. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science. 2006;311:1775–1778. [PubMed]
16. Chong A.S., et al. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science. 2006;311:1774–1775. [PubMed]
17. Suri A., et al. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science. 2006;311:1778–1780. [PubMed]
18. Melton D.A. Reversal of type 1 diabetes in mice. N. Engl. J. Med. 2006;355:89–90. [PubMed]
19. Halban P.A. Cellular sources of new pancreatic beta cells and therapeutic implications for regenerative medicine. Nat. Cell Biol. 2004;6:1021–1025. [PubMed]
20. Bonner-Weir S., Weir G.C. New sources of pancreatic beta-cells. Nat. Biotechnol. 2005;23:857–861. [PubMed]
21. Dor Y., Brown J., Martinez O.I., Melton D.A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 2004;429:41–46. [PubMed]
22. Heit J.J., Karnik S.K., Kim S.K. Intrinsic regulators of pancreatic beta-cell proliferation. Annu. Rev. Cell Dev. Biol. 2006;22:311–338. [PubMed]
23. Milo-Landesman D., et al. Correction of hyperglycemia in diabetic mice transplanted with reversibly immortalized pancreatic beta cells controlled by the tet-on regulatory system. Cell Transplant. 2001;10:645–650. [PubMed]
24. Eldor R., et al. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc. Natl. Acad. Sci. U. S. A. 2006;103:5072–5077. [PubMed]
25. Lee P., et al. Conditional lineage ablation to model human diseases. Proc. Natl. Acad. Sci. U. S. A. 1998;95:11371–11376. [PubMed]
26. Yamaizumi M., Mekada E., Uchida T., Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15:245–250. [PubMed]
27. Herrera P.L. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development. 2000;127:2317–2322. [PubMed]
28. Shapiro A.M., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 2000;343:230–238. [PubMed]
29. Ryan E.A., et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060–2069. [PubMed]
30. Truong W., Lakey J.R., Ryan E.A., Shapiro A.M. Clinical islet transplantation at the University of Alberta — the Edmonton experience. Clin. Transpl. 2005;0:153–172. [PubMed]
31. Shapiro A.M., et al. International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 2006;355:1318–1330. [PubMed]
32. Molano R.D., et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. Transplantation. 2003;75:1812–1819. [PubMed]
33. Lopez-Talavera J.C., et al. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology. 2004;145:467–474. [PubMed]
34. Meier J.J., et al. Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia. 2006;49:1838–1844. [PubMed]
35. Meier J.J., Bhushan A., Butler A.E., Rizza R.A., Butler P.C. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48:2221–2228. [PubMed]
36. Sherry N.A., et al. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes. 2006;55:3238–3245. [PubMed]
37. Eizirik D.L., Spencer P., Kisby G.E. Potential role of environmental genotoxic agents in diabetes mellitus and neurodegenerative diseases. Biochem. Pharmacol. 1996;51:1585–1591. [PubMed]
38. Kushner J.A., et al. Pdx1 restores beta cell function in Irs2 knockout mice. J. Clin. Invest. 2002;109:1193–1201. doi: 10.1172/JCI200214439. [PMC free article] [PubMed] [Cross Ref]
39. Georgia S., Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J. Clin. Invest. 2004;114:963–968. doi: 10.1172/JCI200422098. [PMC free article] [PubMed] [Cross Ref]
40. Teta M., Rankin M.M., Long S.Y., Stein G.M., Kushner J.A. Growth and regeneration of adult Beta cells does not involve specialized progenitors. Dev. Cell. 2007;12:817–826. [PubMed]
41. Brennand K., Huangfu D., Melton D. All beta cells contribute equally to islet growth and maintenance. PLoS Biol. 2007;5:e163. [PMC free article] [PubMed]
42. Gershengorn M.C., et al. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science. 2004;306:2261–2264. [PubMed]
43. Ouziel-Yahalom L., et al. Expansion and redifferentiation of adult human pancreatic islet cells. Biochem. Biophys. Res. Commun. 2006;341:291–298. [PubMed]
44. Weinberg N., Ouziel-Yahalom L., Knoller S., Efrat S., Dor Y. Lineage tracing evidence for in vitro dedifferentiation, but rare proliferation, of mouse pancreatic {beta} cells. Diabetes. 2007;56:1299–1304. [PubMed]
45. Atouf F., et al. No evidence for mouse pancreatic beta-cell epithelial-mesenchymal transition in vitro. Diabetes. 2007;56:699–702. [PubMed]
46. Chase L.G., Ulloa-Montoya F., Kidder B.L., Verfaillie C.M. Islet-derived fibroblast-like cells are not derived via epithelial-mesenchymal transition from Pdx-1 or insulin-positive cells. Diabetes. 2007;56:3–7. [PubMed]
47. Morton R.A., Geras-Raaka E., Wilson L.M., Raaka B.M., Gershengorn M.C. Endocrine precursor cells from mouse islets are not generated by epithelial-to-mesenchymal transition of mature beta cells. Mol. Cell. Endocrinol. 2007;270:87–93. [PMC free article] [PubMed]
48. Ryoo H.D., Gorenc T., Steller H. Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways. Dev. Cell. 2004;7:491–501. [PubMed]
49. Weir G.C., Bonner–Weir S. Five stages of evolving beta–cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl. 3):S16–S21. [PubMed]
50. Teta M., Long S.Y., Wartschow L.M., Rankin M.M., Kushner J.A. Very slow turnover of beta-cells in aged adult mice. Diabetes. 2005;54:2557–2567. [PubMed]
51. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science. 1997;276:60–66. [PubMed]
52. Jensen J.N., et al. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. Gastroenterology. 2005;128:728–741. [PubMed]
53. Rother K.I., Harlan D.M. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J. Clin. Invest. 2004;114:877–883. doi: 10.1172/JCI200423235. [PMC free article] [PubMed] [Cross Ref]
54. Heit J.J., et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443:345–349. [PubMed]
55. Lobe C.G., et al. Z/AP, a double reporter for cre-mediated recombination. Dev. Biol. 1999;208:281–292. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation